Diamyd Medical AB (publ) (DMYD-B.ST) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from published company financials, balance sheet as of 2026-05-31. DMYD-B.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 232.28% | 30.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 85.12% | 33.00% | Fail |
| Non-liquid assets | 14.87% | at least 20.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 85.12% | 33.33% | Fail |
| Accounts receivable | 85.13% | 33.33% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 85.12% | 33.33% | Fail |
| Accounts receivable | 85.13% | 50.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 23.95% | 33.00% | Pass |
| Accounts receivable | 0.00% | 33.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 24.16% | 49.00% | Pass |
| Accounts receivable | 0.00% | 49.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 24.16% | 33.33% | Pass |
| Accounts receivable | 24.16% | 49.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 44.00 | NEUTRAL |
| Stochastic %K (14) | 29.03 | NEUTRAL |
| CCI (20) | -77.91 | NEUTRAL |
| Williams %R (14) | -70.97 | NEUTRAL |
| MACD (12,26,9) | -0.00 | SELL |
| ROC (10) | -0.79 | SELL |
| Momentum (10) | -0.01 | SELL |
| EMA (10) | 1.02 | SELL |
| SMA (10) | 1.02 | SELL |
| EMA (20) | 1.02 | SELL |
| SMA (20) | 1.03 | SELL |
| EMA (30) | 1.04 | SELL |
| SMA (30) | 1.03 | SELL |
| EMA (50) | 1.18 | SELL |
| SMA (50) | 1.05 | SELL |
| EMA (100) | 2.31 | SELL |
| SMA (100) | 1.09 | SELL |
| EMA (200) | 5.71 | SELL |
| SMA (200) | 6.33 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.